March 3, 2026Open Access

COPD and vitamin K antagonism: a cohort study of 1-year all-cause mortality and risk of hospitalisation due to a severe exacerbation

Key Points

VKA treatment is linked to a reduced risk of hospitalisation and mortality in cases of AE-COPD, highlighting its potential effectiveness.
The main finding shows that VKA reduced hospitalisation risk significantly compared to DOAC, though it did not reach statistical significance for mortality.

Structured PICO

Does VKA treatment reduce 1-year all-cause mortality and risk of hospitalisation due to severe exacerbation in patients with COPD compared to DOAC?

Population

Patients with COPD

Intervention

Vitamin K antagonists (VKA)

Comparator

Direct oral anticoagulants (DOAC)

Outcome

1-year all-cause mortality and risk of hospitalisation due to a severe exacerbationhard clinical

In patients with COPD, VKA treatment may be associated with a lower risk of 1-year mortality and severe exacerbation hospitalizations compared to DOACs, though findings lost statistical significance in sensitivity analyses.

Abstract

VKA treatment was associated with a reduction in risk of AE-COPD hospitalisation and mortality compared to DOAC. Sensitivity analysis was consistent with the main analysis; however, it did not reach statistical significance.

Bookmark

View Full Paper